<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057806</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20210528H</org_study_id>
    <nct_id>NCT05057806</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan</brief_title>
  <official_title>Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Ketones, and Cardiovascular Benefit Research Plan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Doris Duke Charitable Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma&#xD;
      ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle&#xD;
      bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study team will examine effects of elevated plasma ketones caused by 12-week treatment&#xD;
      with an SGLT2i (empagliflozin) treatment in participants with T2DM and HF. The study team&#xD;
      will focus on three possible mechanisms of action for these effects and test the following:&#xD;
&#xD;
      (i) Skeletal muscle bioenergetics. Using 31P-MRS, the team will quantitate phosphocreatine&#xD;
      [PCr], ATP, inorganic phosphate, phosphodiester, and intracellular pH. With 1H-MRS, and will&#xD;
      measure intramyocellular lipid content at rest and ATPmax production after exercise. The team&#xD;
      will examine the relationships between phosphorous metabolite concentrations,&#xD;
      intramyocellular lipid content, and ATP generation before and after 12 weeks of SGLT2&#xD;
      inhibition.&#xD;
&#xD;
      (ii) Cardiopulmonary functional capacity.&#xD;
&#xD;
      (iii) Improvements in Patient-Reported Outcomes (PRO). The Patient-Reported Outcomes Measure&#xD;
      Information System (PROMIS) Item Bank v2.0 - Physical Function - Short Form 20a will be used&#xD;
      to evaluate self-reported physical function and well-being. This tool is a well-developed and&#xD;
      validated method to obtain patient self-reported parameters of health in adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized (2:1) placebo controlled double blind study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigators will be blinded to the randomization.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Phosphocreatine</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>A measure of phosphocreatine change from baseline to study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Adenosine Triphosphate (ATP)</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>A measure of ATP change from baseline to study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Inorganic Phosphate</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>A measure of inorganic phosphate change from baseline to study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Phosphodiester</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>A measure of phosphodiester change from baseline to study end</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ATPmax production</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Exercise induced ATPmax production change</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Beta-hydroxybutyrate (β-OH-B)</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change in β-OH-B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acetoacetate concentrations</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change in acetoacetate concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary Function</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change in cardiopulmonary functional capacity using oxygen uptake (VO2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change in the distance that can be covered in a 6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-Reported Outcomes Measure Information System (PROMIS)</measure>
    <time_frame>Baseline to 3 months</time_frame>
    <description>Change in Physical function will be assessed by the PROMIS Item band v2.0 -Physical Function -Short Form 20a to evaluate patient-reported outcomes of physical function and well being.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Empagliflozin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized 2:1 to receive empagliflozin, 25mg/day for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive the empagliflozin placebo for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>Empagliflozin 25MG will be administered orally once per day for 3 months</description>
    <arm_group_label>Empagliflozin Group</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo will be administered orally once per day for 3 months</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo for Empagliflozin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 Diabetes Mellitus&#xD;
&#xD;
          -  Class II-III New York Heart Association (NYHA) heart failure and reduced ejection&#xD;
             fraction (EF) &lt;50%&#xD;
&#xD;
          -  Age 18-80 years&#xD;
&#xD;
          -  BMI 23-38 kg/m2&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) 5.5-10%&#xD;
&#xD;
          -  Blood Pressure (BP) ≤ 145/85 mmHg&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥30 ml/min•1.73 m2&#xD;
&#xD;
          -  Stable dose of guideline-directed medications for heart failure&#xD;
&#xD;
          -  Stable body weight (±4 pounds) over the last 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects treated with an SGLT2 inhibitor, a glucagon-like peptide-1 receptor agonist&#xD;
             (GLP-1 RA) or pioglitazone&#xD;
&#xD;
          -  Resting heart rate &gt;120 bpm&#xD;
&#xD;
          -  Systolic BP&gt;180mmHg and/or diastolic BP &gt;100mmHg&#xD;
&#xD;
          -  Resting percentage of blood oxygen saturation (SpO2) &lt; 85%&#xD;
&#xD;
          -  Physical disability preventing safe performance of the exercise protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina Solis-Herrera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center San Antonio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolina Solis-Herrera, MD</last_name>
    <phone>210-567-6691</phone>
    <email>solisherrera@uthscas.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuejuan (Jane) Qin, PhD</last_name>
    <email>qiny@uthscsa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texas Diabetes Institute - University Health System</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Carolina Solis-Herrera, MD</last_name>
      <phone>210-358-7200</phone>
      <email>solisherrera@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yuejuan Qin, PhD</last_name>
      <email>Qiny@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Carolina Solis-Herrera, MD</last_name>
      <phone>210-567-6691</phone>
      <email>solisherrera@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yuejuan (Jane) Qin, PhD</last_name>
      <email>qiny@uthscsa.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ketones</keyword>
  <keyword>Cardiovascular benefit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The PI will actively participate in journal clubs and symposia and present abstracts at national meetings, as well as submitting manuscripts to top peer-reviewed journals.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

